logo-loader

Abzena strikes antibody deal with US biotech

Published: 07:43 22 Dec 2016 GMT

Antibody
The company licensed an antibody sequence to Trieza Therapeutics

Abzena plc (LON:ABZA) could receive up to US$35mln in development and commercial milestone payments and royalties from an antibody sequence it has licensed to a US biotech start-up.

Cambridge, Massachusetts-based Trieza Therapeutics will use the Abzena antibodies alongside its own viral vector technology to develop cancer drugs.

"This new licence deal with Trieza provides the opportunity for Abzena to benefit from the commercialisation of one of the assets originally developed by the group to exemplify its proprietary antibody humanisation and de-immunisation technology,” said John Burt, chief executive of the UK group.

The firm has its enabling IP embedded in 11 drug candidates, known as ‘Abzena Inside’ products.   

Accesso's landmark deal with SEVEN marks strategic growth in the Saudi Market

Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) chief executive Steve Brown joins Proactive's Stephen Gunnion with details of a significant partnership with Saudi Entertainment Ventures (SEVEN). Brown noted the collaboration highlights accesso's strategy to grow its global footprint,...

22 minutes ago